PMID- 37552101
OWN - NLM
STAT- MEDLINE
DCOM- 20230809
LR  - 20230809
IS  - 1744-8298 (Electronic)
IS  - 1479-6678 (Linking)
VI  - 19
IP  - 6
DP  - 2023 May
TI  - Tirzepatide for the treatment of heart failure in Type 2 diabetes mellitus: 
      (SUR)PASS, or not?
PG  - 301-312
LID - 10.2217/fca-2022-0112 [doi]
AB  - Type 2 diabetes mellitus (T2DM) is a rising pandemic, while cardiovascular 
      disease, including heart failure, represents a frequent concomitance, increasing 
      overall morbidity and mortality and, of course, healthcare cost. Tirzepatide is a 
      dual agonist of glucose-dependent insulinotropic polypeptide and glucagon-like 
      peptide-1 receptors, constituting a novel treatment option in T2DM. This agent 
      exerts additional effects in addition to improvement in glycemic control, which 
      can be of benefit for individuals with T2DM, especially those at risk for or with 
      established cardiovascular disease or heart failure. Current evidence is limited, 
      although suggestive of the cardiovascular safety of tirzepatide. This article 
      provides an overview of available evidence regarding the use of tirzepatide in 
      T2DM, with emphasis on clinical efficacy.
FAU - Patoulias, Dimitrios
AU  - Patoulias D
AUID- ORCID: 0000-0002-6899-684X
AD  - Second Department of Internal Medicine, European Interbalkan Medical Center, 
      Thessaloniki, Asklipiou 10, 57001, Greece.
AD  - Second Department of Cardiology, Aristotle University of Thessaloniki, General 
      Hospital 'Hippokration', Konstantinoupoleos 49, 54642, Thessaloniki, Greece.
FAU - Dimosiari, Athina
AU  - Dimosiari A
AD  - Second Department of Internal Medicine, European Interbalkan Medical Center, 
      Thessaloniki, Asklipiou 10, 57001, Greece.
FAU - Fragakis, Nikolaos
AU  - Fragakis N
AD  - Second Department of Cardiology, Aristotle University of Thessaloniki, General 
      Hospital 'Hippokration', Konstantinoupoleos 49, 54642, Thessaloniki, Greece.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230721
PL  - England
TA  - Future Cardiol
JT  - Future cardiology
JID - 101239345
RN  - OYN3CCI6QE (tirzepatide)
RN  - 59392-49-3 (Gastric Inhibitory Polypeptide)
RN  - 0 (Hypoglycemic Agents)
SB  - IM
MH  - Humans
MH  - *Cardiovascular Diseases
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy
MH  - *Heart Failure/complications/drug therapy
MH  - Gastric Inhibitory Polypeptide
MH  - Hypoglycemic Agents/therapeutic use
OTO - NOTNLM
OT  - Type 2 diabetes
OT  - cardiovascular disease
OT  - glucagon-like peptide-1
OT  - glucose-dependent insulinotropic polypeptide
OT  - heart failure
OT  - incretin
OT  - tirzepatide
EDAT- 2023/08/08 12:42
MHDA- 2023/08/09 06:43
CRDT- 2023/08/08 10:13
PHST- 2023/08/09 06:43 [medline]
PHST- 2023/08/08 12:42 [pubmed]
PHST- 2023/08/08 10:13 [entrez]
AID - 10.2217/fca-2022-0112 [doi]
PST - ppublish
SO  - Future Cardiol. 2023 May;19(6):301-312. doi: 10.2217/fca-2022-0112. Epub 2023 Jul 
      21.